American Journal of Cardiology
Volume 105, Issue 3 , Pages 352-358, 1 February 2010

Age-Modification of Lipoprotein, Lipid, and Lipoprotein Ratio-Associated Risk for Coronary Artery Calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA])

  • Pathmaja Paramsothy, MD

      Affiliations

    • Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington
    • Corresponding Author InformationCorresponding author: Tel: (206) 744-9119; fax: (206) 744-9989
  • ,
  • Ronit Katz, PhD

      Affiliations

    • Department of Biostatistics, University of Washington, Seattle, Washington
  • ,
  • David S. Owens, MD

      Affiliations

    • Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington
  • ,
  • Gregory L. Burke, MD, MS

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina
  • ,
  • Jeffrey L. Probstfield, MD

      Affiliations

    • Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington
  • ,
  • Kevin D. O'Brien, MD

      Affiliations

    • Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington

Received 16 July 2009; received in revised form 20 September 2009; accepted 20 September 2009. published online 23 December 2009.

Although abnormal lipoproteins and lipoprotein ratios are powerful risk factors for clinical cardiovascular events, these associations are stronger in younger than in older subjects. Whether age modifies the relation of lipoproteins and lipoprotein ratios to the relative risk of subclinical cardiovascular disease (CVD), as assessed by coronary artery calcium (CAC) scores, has not been examined in a contemporary, multiethnic cohort. We performed multivariate relative risk regression analyses to determine the relative risks for associations of lipoproteins and lipoprotein ratios with prevalent CAC in participants in Multi-Ethnic Study of Atherosclerosis (MESA). The participants were community-dwelling adults aged 45 to 84 years without clinically apparent CVD at baseline. We excluded those taking lipid-lowering therapy (15%) and stratified the results by decades of age. A total of 5,092 participants met the inclusion criteria. In the fully adjusted models, per SD of low-density lipoprotein, the age-stratified, adjusted relative risk for CAC was 1.17 (95% confidence interval [CI] 1.07 to 1.28) for those aged 45 to 84 years but was 1.05 (95% CI 1.01 to 1.10) for those aged 75 to 84 years (p-interaction = 0.12). The relative risk per SD of total/high-density lipoprotein cholesterol ratio was 1.20 (95% CI 1.12 to 1.29) for those aged 45 to 54 years but only 1.04 (95% CI 1.00 to 1.09) for those aged 75 to 84 years (p-interaction <0.001). The lipoproteins levels and lipoprotein ratios were associated with increased relative risks for CAC across all age categories. However, these associations were markedly attenuated by age. In conclusion, abnormal lipoprotein levels in middle age are a powerful risk factor for early atherosclerosis, as manifested by prevalent CAC.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This research was supported by contracts N01-HC-95159 through N01-HC-95165 and N01-HC-95167 from the National Heart, Lung and Blood Institute, Bethesda, Maryland. Dr. Paramsothy is funded by grant 1KL2RR025015-01 from the National Center for Research Resources, a component of the National Institutes of Health, and National Institutes of Health Roadmap for Medical Research, Bethesda, Maryland. Dr. Paramsothy has received grant support from Pfizer Pharmaceuticals, New York, New York, that was not directly for support of this project. Dr. O'Brien has received speaking honoraria or grant support from AstraZeneca, Bristol Myers-Squibb, Merck, and Abbott Pharmaceuticals.

 Its contents are solely the responsibility of the authors and do not necessarily represent the official view of National Center for Research Resources or National Institutes of Health.

PII: S0002-9149(09)02411-4

doi:10.1016/j.amjcard.2009.09.040

American Journal of Cardiology
Volume 105, Issue 3 , Pages 352-358, 1 February 2010